Dr. Shubham Pant is a Professor in the Department of Gastrointestinal (GI) Medical Oncology with a joint appointment in the Department of Investigational Cancer Therapeutics (Phase I Center) at The University of Texas MD Anderson Cancer Center. Dr. Pant is recognized as an international expert in Gastrointestinal Cancers with an emphasis on Pancreatic and Biliary cancers and Phase 1 trials.

Dr. Pant's research focuses on novel immunotherapeutic approaches and targeted therapies in GI cancers, including devising novel ways to target the KRAS mutation. He has been the lead/co-lead of several global practice-changing studies, including “Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicenter, single-arm, phase 2b study”; “Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation” and “Erdafitinib in patients with advanced solid tumors with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study”; amongst others. He has over 100 peer-reviewed publications and has published in high-impact journals, including The Lancet, Lancet Oncology, and Journal of Clinical Oncology. He is frequently invited to present his research at national and international meetings. He collaborates on numerous grants, including R01 and SPORE grants funded by the National Institute of Health. Dr. Pant serves on the National Cancer Institute (NCI) Pancreas Task Force and the Pancreatic Cancer Action Network's (PanCan) Scientific and Medical Advisory Board. He also helped draft the American Society of Clinical Oncology (ASCO) Metastatic Pancreatic Cancer Guidelines, which provide evidence-based recommendations for physicians. He is also the editor of the book Pancreatic Cancer: Current Therapeutics and Future Directions. (Publisher: Springer).

Dr. Pant completed his fellowship from the James Cancer Hospital/Solove Research Institute at the Ohio State University, where he was elected Chief Fellow. He has previously served as the Director of Clinical Trials, Section of Hematology, and Associate Director of the TSET Phase I Program at the University of Oklahoma. He was the recipient of the Mai Eager Anderson Endowed Chair in Cancer Clinical Trials. He was featured in "40 under 40" in Oklahoma magazine and has been voted by his peers as "America's Top Doctors" five years in a row. For his patient care, he was awarded the Golden Pillar Award for Outstanding Patient Service twice for achieving patient satisfaction scores in the top 90th percentile as measured by the OU Medicine EXCEL initiative.

Dr. Pant has an interest in improving the quality of care for cancer patients, is a Lean Six Sigma Green Belt, and has served on the ASCO Quality of Care Committee and ASCO's International Quality Task Force. Dr. Pant was also selected for the prestigious ASCO Leadership Development Program.